Health reform must bolster innovation
The authors argue that global health systems must prioritize innovation alongside structural reform to address evolving threats like drug-resistant pathogens. They suggest that product development partnerships are essential for creating new medicines that traditional market-driven models often ignore.
Why it matters
It highlights the critical need for collaborative funding models to solve global health crises that are not profitable for private pharmaceutical companies.
Manica Balasegaram & Martin Fitchet
The article focuses on policy and systemic health infrastructure without partisan political framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in